Division of Sanofi
Latest From Chattem Inc.
Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US
National Advertising Division review. NAD also recommended modifying claims suggesting Xyzal's pharmacological design confers a clinically meaningful benefit over Zyrtec.
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.
Natural products cut into sales of OTC sleep aids as more consumers prefer naturals as non-addictive and not causing grogginess the following day, Kline & Co. research shows. OTC sleep aids posted 3.4% growth in 2016, down from 50% to 15% growth in recent years.
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
- Contact Info
Phone: (615) 821-4571
1715 West 38th St.
P.O. Box 2219 Chattanooga, TN 37409
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.